0001387131-20-007592.txt : 20200817 0001387131-20-007592.hdr.sgml : 20200817 20200817090300 ACCESSION NUMBER: 0001387131-20-007592 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200813 FILED AS OF DATE: 20200817 DATE AS OF CHANGE: 20200817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LEDERMAN SETH CENTRAL INDEX KEY: 0001563420 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36019 FILM NUMBER: 201108066 MAIL ADDRESS: STREET 1: C/O TONIX PHARMACEUTICALS HOLDING CORP STREET 2: 509 MADISON AVE., SUITE 306 CITY: NEW YORK STATE: NY ZIP: 10022 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Tonix Pharmaceuticals Holding Corp. CENTRAL INDEX KEY: 0001430306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261434750 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 1608 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 1-800-849-7894 MAIL ADDRESS: STREET 1: 509 MADISON AVE. - SUITE 1608 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: TAMANDARE EXPLORATIONS INC. DATE OF NAME CHANGE: 20080320 4 1 lederman-form4_0813020.xml OWNERSHIP DOCUMENT X0306 4 2020-08-13 0 0001430306 Tonix Pharmaceuticals Holding Corp. TNXP 0001563420 LEDERMAN SETH C/O TONIX PHARMACEUTICALS HOLDING CORP 509 MADISON AVE., SUITE 306 NEW YORK NY 10022 1 1 0 0 Chief Executive Officer Common Stock, $0.001 par value 2020-08-13 4 P 0 60000 0.91 A 83267 I By 401(k) plan Common Stock, $0.001 par value 459 I By IRA Account Common Stock, $0.001 par value 177 D Common Stock, $0.001 par value 31 I By spouse Common Stock, $0.001 par value 30 I By Leder Laboratories, Inc. Common Stock, $0.001 par value 30 I By Starling Pharmaceuticals, Inc. Common Stock, $0.001 par value 205 I By Lederman & Co., LLC Common Stock, $0.001 par value 33 I By L&L Technologies, LLC Common Stock, $0.001 par value 59 I By Targent Pharmaceuticals, LLC Reporting person may be deemed to be a control person of this entity. /s/ Seth Lederman 2020-08-17